Salarius Pharmaceuticals Inc Cash Flow Conversion Efficiency
Salarius Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Salarius Pharmaceuticals Inc (SLRX) has a cash flow conversion efficiency ratio of -0.388x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.65 Million) by net assets ($4.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Salarius Pharmaceuticals Inc (2015–2024)
Cash flow conversion efficiency of Salarius Pharmaceuticals Inc from 2015 to 2024. This chart illustrates how Salarius Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Salarius Pharmaceuticals Inc share price for real-time trading data and today's change.
Salarius Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Salarius Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Salarius Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Salarius Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Salarius Pharmaceuticals Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CASA DE BUCOVINA-CLUB DE MUNTE
RO:BCM
|
-0.009x |
|
THOR MNG CUFS/1LS- 00001
F:T5MB
|
N/A |
|
Opyl Ltd
AU:OPL
|
1.994x |
|
Destiny Media Technologies Inc
V:DSY
|
0.158x |
|
Stenocare AS
CO:STENO
|
0.180x |
|
JATCORP LTD.
F:3J2
|
N/A |
|
DomaCom Limited
AU:DCL
|
0.000x |
|
Chenghe Acquisition II Co.
NYSE MKT:CHEB
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Salarius Pharmaceuticals Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Salarius Pharmaceuticals Inc from 2015 to 2024. Review Salarius Pharmaceuticals Inc financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.51 Million | $-4.53 Million | -2.994x | -23.21% |
| 2023-12-31 | $5.29 Million | $-12.85 Million | -2.430x | -43.39% |
| 2022-12-31 | $10.38 Million | $-17.60 Million | -1.694x | -543.23% |
| 2021-12-31 | $38.72 Million | $-10.20 Million | -0.263x | +43.39% |
| 2020-12-31 | $22.16 Million | $-10.31 Million | -0.465x | +57.48% |
| 2019-12-31 | $10.58 Million | $-11.58 Million | -1.094x | +56.95% |
| 2018-12-31 | $9.28 Million | $-23.60 Million | -2.542x | -166.91% |
| 2017-12-31 | $29.11 Million | $-27.72 Million | -0.952x | -76.27% |
| 2016-12-31 | $59.32 Million | $-32.05 Million | -0.540x | -140.12% |
| 2015-12-31 | $92.19 Million | $-20.75 Million | -0.225x | -- |
About Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufac… Read more